Nexalin Technology (NXL) EBT Margin (2021 - 2026)
Nexalin Technology (NXL) posted EBT Margin of 18412.71% for Q2 2026, down 31.28% on a QoQ basis from 14025.67% in Q1 2026, and down 1617297.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Nexalin Technology (NXL) EBT Margin (2021 - 2026) Analysis & Trends
Nexalin Technology has reported EBT Margin for 6 years, with the latest figure at 18412.71% in Q2 2026.
- On a quarterly basis, EBT Margin fell 1617297.0% year-over-year to 18412.71% in Q2 2026; TTM through Jun 2026 was 4139.44%, a 92321.0% increase from a year earlier, with the FY2025 full-year figure at 2725.46%, up 178615.0% from the prior year.
- EBT Margin was 18412.71% for Q2 2026 at Nexalin Technology, down from 14025.67% in the prior quarter.
- The five-year high for EBT Margin was 55.68% in Q3 2022, with the low at 18412.71% in Q2 2026.
- Average EBT Margin over 5 years is 5393.03%, with a median of 3125.23% recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: EBT Margin surged 904260 bps in 2025, then sank 1617297 bps in 2026.
- Over 5 years, EBT Margin stood at 1917.86% in 2022, then sank by 98 bps to 3801.47% in 2023, then slumped by 174 bps to 10425.24% in 2024, then jumped by 87 bps to 1382.63% in 2025, then tumbled by 1232 bps to 18412.71% in 2026.
- The last three EBT Margin figures came in at 18412.71% (Q2 2026), 14025.67% (Q1 2026), and 1382.63% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 12.10% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 36.46% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 18.13% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 23.74% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 19.48% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 29.86% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -1.65% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 24.27% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 18.32% |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | -18,412.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18,412.71% |
| Mar 31, 2026 | -14,025.67% |
| Dec 31, 2025 | -1,382.63% |
| Sep 30, 2025 | -12,542.35% |
| Jun 30, 2025 | -2,239.74% |
| Mar 31, 2025 | -4,845.27% |
| Dec 31, 2024 | -10,425.24% |
| Sep 30, 2024 | -6,795.30% |
| Jun 30, 2024 | -4,780.93% |
| Mar 31, 2024 | -1,330.78% |
| Dec 31, 2023 | -3,801.47% |
| Sep 30, 2023 | -9,526.77% |
| Jun 30, 2023 | -2,314.12% |
| Mar 31, 2023 | -2,449.00% |
| Dec 31, 2022 | -1,917.86% |
| Sep 30, 2022 | -55.68% |
| Jun 30, 2022 | -107.44% |
| Mar 31, 2022 | -121.63% |
| Dec 31, 2021 | -2,483.14% |
| Sep 30, 2021 | -3,256.43% |